MHC class I antigen presentation and implications for developing a new generation of therapeutic vaccines.
about
Immunological interactions in radiotherapy-opening a new window of opportunityCancer stem cells and immunoresistance: clinical implications and solutionsUnderstanding the Impact of ErbB Activating Events and Signal Transduction on Antigen Processing and Presentation: MHC Expression as a Model.Dengue virus specific dual HLA binding T cell epitopes induce CD8+ T cell responses in seropositive individuals.Immunobiology and signaling pathways of cancer stem cells: implication for cancer therapy.Flagellin is a strong vaginal adjuvant of a therapeutic vaccine for genital cancer.Generation of human MHC (HLA-A11/DR1) transgenic mice for vaccine evaluation.Human Leukocyte Antigen (HLA) Peptides Derived from Tumor Antigens Induced by Inhibition of DNA Methylation for Development of Drug-facilitated Immunotherapy.CancerPDF: A repository of cancer-associated peptidome found in human biofluids.Menin Plays a Critical Role in the Regulation of the Antigen-Specific CD8+ T Cell Response upon Listeria Infection.Engineering challenges for brain tumor immunotherapy.Artificial human antigen-presenting cells are superior to dendritic cells at inducing cytotoxic T-cell responses.Immunoproteasome deficiency in non-small cell lung cancer and its relevance to immunotherapy.Short peptide epitope design from hantaviruses causing HFRS.MHC class I loaded ligands from breast cancer cell lines: A potential HLA-I-typed antigen collection.HLA-A24 ligandome analysis of colon and lung cancer cells identifies a novel cancer-testis antigen and a neoantigen that elicits specific and strong CTL responses.Current challenges for cancer vaccine adjuvant development.Targeting tumor microenvironment to curb chemoresistance via novel drug delivery strategies.Metabolic Adaptation of Human CD4+ and CD8+ T-Cells to T-Cell Receptor-Mediated Stimulation.Immunotherapy for Breast Cancer: Current and Future Strategies.PhysiCell: An open source physics-based cell simulator for 3-D multicellular systems.In silico-guided sequence modifications of K-ras epitopes improve immunological outcome against G12V and G13D mutant antigensFine mapping of MHC region in lung cancer highlights independent susceptibility loci by ethnicityA neoepitope derived from a novel human germline APC gene mutation in familial adenomatous polyposis shows selective immunogenicityA cancer vaccine approach for personalized treatment of Lynch Syndrome
P2860
Q26767178-FD709FD6-40BC-4C2D-80FE-320FF897A81AQ26769757-BFDA1409-C646-4C8E-AB1D-E6244D570BBCQ27691330-8E6AA801-0EB8-4BD8-B943-690610D42DF2Q35886539-579867BE-9089-493D-AEE5-39851BA8DF9AQ35984406-4B477413-4914-453A-B500-F488E7F990A8Q36711018-15BECA40-7186-4408-AA31-632198FE0176Q37135201-18F4D7B0-A387-45E9-B77F-E3DD42038CA4Q38390185-2C591E23-7B78-4E13-A98F-1E26587D146BQ38803215-23FDAECD-62FF-47AC-994B-4BB7F8263BD1Q39231572-D9420002-1FAE-42A1-80A1-508C2DCF004AQ39381281-47F0E36C-5BF1-4DE8-A603-71A7DBD0A8BBQ40140002-2D9D728A-3B45-4C07-ADD3-7F86EEDE7A53Q41428789-85992F2A-A8BF-45D2-B0C5-5B6D47BD4352Q41698233-2F8F006A-1BDB-48D3-936C-69BBAA141F66Q47560871-A7801496-4749-4E0F-94A7-A6112F156CF3Q47835567-58D3E750-44A6-427E-A8B1-2E9EE18FC3A6Q48160317-181277F8-D82D-4691-A2F9-72FA05390495Q48308048-F3FE3FE6-AAB2-4CAE-9460-20F84458EDF2Q49464460-BDF83681-8238-4D5E-8FC2-83085C56CB91Q52587066-55D8A80C-64DC-427E-9C09-DBF4FF7FEDE0Q52688323-04D142A1-6CBD-4A6F-98C1-4CBFAEDD74BFQ57175287-479B3E85-22A5-4344-AFEE-80E60DE7ABACQ58351991-443EBD5C-DE9F-470A-AFF3-C4804C10090BQ58696044-969F417F-32E1-4AFD-A074-535D38C000DBQ58782820-B3FA9194-9A53-47A7-A3EE-EF9AA3550C2C
P2860
MHC class I antigen presentation and implications for developing a new generation of therapeutic vaccines.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on May 2014
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
MHC class I antigen presentati ...... ation of therapeutic vaccines.
@en
MHC class I antigen presentati ...... ation of therapeutic vaccines.
@nl
type
label
MHC class I antigen presentati ...... ation of therapeutic vaccines.
@en
MHC class I antigen presentati ...... ation of therapeutic vaccines.
@nl
prefLabel
MHC class I antigen presentati ...... ation of therapeutic vaccines.
@en
MHC class I antigen presentati ...... ation of therapeutic vaccines.
@nl
P2860
P356
P1476
MHC class I antigen presentati ...... ation of therapeutic vaccines.
@en
P2093
Joseph D Comber
Ramila Philip
P2860
P356
10.1177/2051013614525375
P577
2014-05-01T00:00:00Z